Alphyn Biologics bags $25 million financing to advance breakthrough skin disease therapies
Alphyn is developing Zabalafin Hydrogel as the first therapy to simultaneously tackle the interconnected drivers of AD
Alphyn is developing Zabalafin Hydrogel as the first therapy to simultaneously tackle the interconnected drivers of AD
Clinical trial enrollment has long been a bottleneck in drug development
WINREVAIR is currently the first and only activin signalling inhibitor approved for PAH across all 27 EU member states
These building blocks are essential to modern therapeutics, including fast-growing GLP-1 treatments for weight loss and diabetes
Glenmark's Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug
The FDA aims to make a decision by April 8, 2026
The new centre brings advanced corneal procedures pioneered in India
The companies aim to expand treatment options for millions living with metabolic disorders
Subscribe To Our Newsletter & Stay Updated